Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study

Trial Profile

Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Lenvatinib (Primary)
  • Indications Neuroendocrine tumours; Paraganglioma; Phaeochromocytoma; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Apr 2017 Results (n=17) assessing effect of cabozantinib or lenvatinib on body composition in endocrine tumor patients, presented at The 99th Annual Meeting of the Endocrine Society.
    • 16 Nov 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov. record.
    • 16 Nov 2015 Planned primary completion date changed from 1 Jan 2019 to 1 Nov 2018 as per NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top